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initiating therapy could be a cost-effective option compared to a PI based initiating 
therapy in the Greek health care setting.
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Objectives: Sofosbuvir (SOF) is a uridine analogue polymerase inhibitor. Ledipasvir 
(LDV) is an inhibitor of the hepatitis C virus (HCV) NS5A protein. Efficacy and safety 
have been demonstrated in three phase III clinical trials of LDV/SOF administered 
with or without ribavirin. This analysis evaluated the long-term outcomes of LDV/
SOF in GT1 treatment-naïve (TN) and treatment-experienced protease inhibitor 
failure patients (TE) HCV patients. MethOds: A Markov-model followed 10,000 
patients for a lifetime, with 19% initiating treatment at the compensated cirrhotic 
(CC) stage. In GT1 TN, LDV/SOF for 8 weeks for non-cirrhotic (NC) patients and 12 
weeks for CC patients was compared against SOF with pegylated interferon 2a and 
ribavirin (SOF/PR), SOF with RBV (SOF/RBV) and simeprevir with PR (SMV/PR). In 
GT1 TE, LDV/SOF for 12 weeks was compared with SOF/PR, SMV/PR and no treat-
ment. SVR rates have been reported as 94% for GT1 TN NC and CC patients, 95% and 
86% for GT1 TE NC and CC respectively. SOF/LDV was also well tolerated without 
any reported grade 3/4 adverse events. Results: SOF/LDV was shown to be highly 
effective in preventing advanced liver disease (ALD) and mortality due to HCV. In 
GT1 TN, LDV/SOF prevented more than 800, 200 and 1600 cases of ALD than SMV/
PR, SOF/PR and SOF/RBV. In GT1 TE over 5000 cases of ALD were avoided compared 
with no treatment and over 1000 compared with SMV/PR, and SOF/PR. LDV/SOF was 
also shown to save more than 10 lives compared with SMV/PR, SOF/PR and SOF/
RBV and avoid the death of 50 TE PI failure patients with no available treatment 
option. cOnclusiOns: LDV/SOF was shown to be highly effective in preventing 
progression to ALD and reducing HCV-related mortality with a well-tolerated single 
tablet regimen. This is particular important for protease inhibitor failure patients 
since there are currently no alternative treatment options.
PIN67
cosT-effecTIveNess aNd LoNg-Term ouTcomes of sovaLdI (sofosbuvIr) 
for The TreaTmeNT of chroNIc hePaTITIs c INfecTed (hcv) PaTIeNTs 
from a swedIsh socIeTaL PersPecTIve
Cure S., Guerra I.
OptumInsight, Uxbridge, UK
Objectives: Sovaldi (sofosbuvir) is the first nucleotide polymerase inhibitor with 
pan-genotypic activity and a high barrier to resistance. Efficacy of sofosbuvir-
based regimens demonstrated > 90% SVR across genotype (GT) 1-6 in five phase 
III clinical trials of sofosbuvir administered with ribavirin or a combination of 
pegylated interferon alfa and ribavirin (PR). Sofosbuvir is also the first all-oral 
24-week option available for patients unsuitable for interferon (UI). This analy-
sis evaluated the cost-effectiveness and long-term outcomes of sofosbuvir in 
Swedish treatment-naïve genotype GT1/4/5/6 patients and GT2 and 3 patients 
who are treatment-naïve, treatment-experienced, interferon eligible (IE) and 
UI. MethOds: A Markov-model followed 10,000 patients for a lifetime, with 20% 
initiating treatment at the compensated cirrhotic stage. For patients IE SOF/PR 
for 12 weeks was compared to telaprevir, boceprevir and PR, showing the highest 
SVR rates and a favourable safety profile. A societal perspective was adopted by 
considering productivity losses associated with treatment and advanced liver 
disease (ALD). Results: Sofosbuvir regimens, including interferon-free, were 
shown to be cost-saving across all genotypes and against all current treatment 
alternatives in Sweden. In GT1, this novel therapy incurs approximately 42%, 31% 
and 25% lower costs than PR, boceprevir and telaprevir, respectively. Sofosbuvir 
also reduces the burden of HCV. In 10,000 patients, we estimated that on average 
1697, 1417, 607 and 204 cases of compensated cirrhosis, decompensated cirrhosis, 
hepatocellular carcinoma and liver transplant, respectively, and 92 deaths could be 
avoided with sofosbuvir-based regimens compared with telaprevir, boceprevir, PR 
and no treatment. cOnclusiOns: Cost-effectiveness analysis based on a Swedish 
societal perspective (i.e. including productivity losses due to treatment and ALD) 
shows sofosbuvir-based treatments to be cost saving in all genotypes and against 
all current treatment alternatives. In order to optimally allocate scarce societal 
resources, arguably all costs related to HCV treatment need to be included in the 
cost-effectiveness analysis.
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Objectives: Other economic evaluation tools than the classical cost-effectiveness 
(CE) analysis exist but the acceptance of these by decision makers is unknown. We 
assessed the value of these new methods among experts and decision makers in 
Europe through a survey. MethOds: Qualitative structured phone-interviews were 
conducted among experts and decision makers in eleven European countries over 
a one year period to evaluate the current and future use of additional economic 
evaluation methods for reimbursement decisions on vaccines. The five additional 
methods were: 1) Return on Investment (RoI); 2) Multi-Criteria Decision Analysis 
(MCDA); 3) Quality of hospital care (QoC); 4) Health care Budget Optimisation (BOM), 
and 5) Macro-Economic Analysis (MEA). Results: One hundred and seventy experts 
were contacted with a 15% participation rate (25 experts participated). In countries 
where CE is formally used like Belgium, the Netherlands, the UK and the Nordic 
countries, the additional methods were considered as relevant by most experts to 
value vaccines: RoI (61%), MCDA (62%), QoC (54%), BOM (54%) and MEA (61%). They 
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Objectives: To evaluate the cost-effectiveness of commonly used antimicrobial reg-
imens in treatment of Community-acquired Pneumonia (CAP) in China. MethOds: 
This was a retrospective study of CAP patients who received different antibiotic 
drugs during their hospitalization in a 1st Class, Grade A hospital in Shenyang, 
Liaoning between January 2011 and June 2012. Cost-effectiveness analysis was 
performed for the common therapeutic regimens based on both clinical practice 
and the main recommended antibacterial treatment of CAP from the perspective 
of society as a whole. For the sensitivity analysis, we used a relative measurement 
method and an absolute measurement method to test the strength of the study’s 
conclusions over a range of assumptions. Results: 203 clinical cases met study 
criteria, and were assigned to the groups of cefuroxime (n= 26), cefmetazole (n= 60), 
cefamandole (n= 32), moxifloxacin hydrochloride (n= 28), erythromycin (n= 28), 
cefmetazole and erythromycin (n= 29). The treatment success rate for the 6 groups 
were 42.31%, 51.67%, 6.25%, 25.0%, 60.71% and 65.52%, respectively, total direct medi-
cal costs were $474.10, $501.21, $1082.43, $1024.46, $404.15 and $555.84, respectively, 
among them, the incremental cost-effectiveness ratio (ICER) of erythromycin group 
and a combination regimen (cefmetazole plus erythromycin) was 31.54, indicating 
that erythromycin and combination of cefmetazole and erythromycin had a positive 
effect on treatment success and a lower total cost. Sensitivity analysis supported 
the dominance of the 2 groups in nearly all scenarios but the variation of treatment 
success rate. cOnclusiOns: Erythromycin monotherapy and a combination of 
cefmetazole and erythromycin were more cost-effective than other regimens in the 
treatment of Community-acquired Pneumonia. Nevertheless, since there was no 
cost-effective threshold in China to compare the cost-effectiveness of the 2 options, 
it remains to be further researched and discussed.
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Objectives: C. difficile is the leading cause of antibiotic associated infectious 
nosocomial diarrhoea. The two main treatments for these patients are fidaxomicin 
and vancomycin. In two phase III randomized controlled trials fidaxomicin was 
found to be non inferior to vancomycin in initial clinical cure of CDI and superior 
in preventing recurrences. The main goal of this economic analysis was to evaluate 
the cost-effectiveness of fidaxomicin versus vancomycin, for the treatment of C. 
difficile infection in Hungary. MethOds: A decision tree model was developed to 
capture the consequences of recurrent infections with both treatment options. 
The model reported two clinical outcomes: clinical cure and recurrent CDI epi-
sodes. Treatment efficacy was estimated through a meta-analysis in a Bayesian 
framework. The model took the third party payer perspective. The incremental 
cost-effectiveness ratio was calculated as the ratio between costs and number of 
avoided recurrent episodes. Uncertainty around model parameters was assessed 
through probabilistic sensitivity analysis. Results: Total average costs for fidax-
omicin and vancomycin therapies were € 3,987 and € 2,505 per patient, respectively. 
The average number of recurrent episodes per patients was lower with fidaxomicin 
therapy (0.13 recurrent episodes/patient) than with vancomycin therapy (0.40 
recurrent episodes/patient). Incremental cost-effectiveness ratio (fidaxomicin 
vs. vancomycin) was € 5,520 per avoided recurrent episode. cOnclusiOns: In 
conclusion, this study found that fidaxomicin has favourable cost-effectiveness 
ratio compared to vancomycin.
PIN65
cosT-effecTIveNess aNaLysIs of raLTegravIr IN hIv-INfecTed 
TreaTmeNT NaIve PaTIeNTs IN greece
Athanasakis K.1, Boubouchairopoulou N.1, Retsa M.P.2, Maiese E.M.3, Elbasha E.H.4, 
Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2MSD Hellas, Athens, Greece, 3Merck & Co, Inc., 
Whitehouse Station, NJ, USA, 4Merck & Co, Inc, Flourtown, PA, USA
Objectives: Despite the success of current antiretroviral therapies for human 
immunodeficiency virus (HIV) infection, the development of drug resistance repre-
sents a critical issue. Raltegravir is an inhibitor of HIV-1 integrase approved for treat-
ment experienced and naive patients. The present study aimed at conducting an 
economic evaluation of raltegravir vs protease inhibitor (PI) regimen in treatment-
naive patients in Greece. MethOds: A three-stage continuous-time Markov model 
was developed using differential equations, for the cost-effectiveness analysis of 
initiating raltegravir-based therapy as first-line treatment vs initiating protease 
inhibitor (PI) -based therapy as first-line therapy, over a lifetime horizon. Stages of 
the model included progression through successive treatment therapies. Patients 
entered the model with a given CD4 cell count and HIV-1 viral load. After they failed 
or discontinued the current therapy, patients transitioned between eighteen health 
states (defined according to CD4-count and HIV-1 viral load), and progressed to the 
next stage. At any time they could develop acquired immunodeficiency syndrome 
(AIDS), suffer from a coronary heart disease (CHD) or die. Model inputs were col-
lected from the literature and adapted to Greek health care setting using expert 
opinion. Model outcomes included projected number of AIDS cases, number of 
CHD events, number of deaths, life expectancy and incremental cost-effectiveness 
ratios (ICER). The analysis was performed from the perspective of the Greek Social 
Insurance. Results: Patients initiating on the raltegravir-based therapy presented 
longer undiscounted life expectancy compared to those initiating on a PI regimen 
(21.20 vs 18.85 years). The ICER for a raltegravir-initiated treatment strategy vs. 
a boosted PI initiated treatment strategy was 12,757/QALY gained (discounted at 
3%). cOnclusiOns: Results suggest that, over a lifetime horizon, raltegravir based 
